癌症生物技术公司ArriVent获得了一个用于胃肠道恶性肿瘤的ADC，并做出了最佳声明-动脉网

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim

MedCity News 等信源发布 2025-01-23 07:43



可切换为仅中文







ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that has potential applications in gastrointestinal cancers.

。

The company on Wednesday announced it paid

该公司周三宣布支付

$47 million up front

4700万美元预付款

to license MRG007, a drug developed by Lepu Biopharma, a Shanghai-based developer of cancer therapies.

获得MRG007的许可，MRG007是一种由上海癌症治疗开发商乐浦生物制药公司开发的药物。

MRG007 is an antibody drug conjugate (ADC), a type of therapy made by linking a toxic drug payload to a targeting antibody. Lepu has not disclosed the target of the drug, nor has ArriVent. But ArriVent said that based on preclinical studies, it believes the Lepu ADC has best-in-class potential.

MRG007是一种抗体-药物偶联物（ADC），一种通过将有毒药物有效载荷与靶向抗体连接而制成的疗法。Lepu没有透露药物的目标，也没有透露。但ArriVent表示，根据临床前研究，它认为Lepu ADC具有同类最佳的潜力。

presented by

提交人

Sponsored Post

3D Medical Animation Services: A Revolution in Healthcare Education and Marketing

3D医学动画服务：医疗保健教育和营销的革命

3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.

3D医学动画服务已成为医疗保健行业的突破性工具，彻底改变了医学概念的教学，理解和营销方式。

By Start Grid

按开始网格

It’s possible the drug class ArriVent is referring to is drugs that target claudin 18.2, a protein highly expressed in gastrointestinal cancers. Claudin 18.2, or CLDN18.2, is a top target for GI cancer drug research. This past October,

药物类别ArriVent可能是指靶向claudin 18.2的药物，claudin 18.2是一种在胃肠道癌症中高度表达的蛋白质。Claudin 18.2或CLDN18.2是胃肠道癌症药物研究的首要目标。今年十月，

Astellas Pharma’s Vyloy became the first FDA-approved CLDN18.2-targeting drug

Astellas Pharma的Vyloy成为第一个FDA批准的CLDN18.2靶向药物

. Vyloy, a monoclonal antibody, is approved for use with chemotherapy to treat advanced cases of gastroesophageal junction adenocarcinoma, a rare type of GI cancer. The Japanese pharma company’s clinical development program for the drug also includes testing the drug in GEJ cancers with a checkpoint inhibitor and chemotherapy.

Vyloy是一种单克隆抗体，被批准与化疗一起用于治疗胃食管连接腺癌（一种罕见的胃肠道癌）的晚期病例。这家日本制药公司的药物临床开发计划还包括使用检查点抑制剂和化疗对GEJ癌症进行药物测试。

A separate study is evaluating the drug in pancreatic adenocarcinoma..

另一项研究正在评估该药物治疗胰腺癌的效果。。

Other companies are pursuing CLDN18.2, but with ADCs. AstraZeneca’s AZD0901 is in Phase 3 testing in advanced gastric and GEJ cancers. Elevation Oncology’s ADC, EO-3021, is in early clinical development for advanced solid tumors, including GI cancers. Data are expected in the first half of this year..

其他公司正在追求CLDN18.2，但有ADC。阿斯利康的AZD0901正在进行晚期胃癌和GEJ癌症的3期测试。Elevation Oncology的ADC EO-3021正处于晚期实体瘤（包括胃肠道癌）的早期临床开发阶段。预计今年上半年会有数据。。

According to ArriVent, MRG007 has shown robust antitumor activity in preclinical models of GI cancers. The research also shows a favorable therapeutic index based on studies that could support an investigational new drug application. The company said it plans a submission for the first half of this year.

据ArriVent称，MRG007在胃肠道癌症的临床前模型中显示出强大的抗肿瘤活性。该研究还显示了一个有利的治疗指数，该指数基于可以支持研究性新药应用的研究。该公司表示，计划在今年上半年提交。

The initial focus will be in colorectal and pancreatic cancers as well as other GI cancers..

最初的重点将是结直肠癌和胰腺癌以及其他胃肠道癌症。。

ArriVent’s most advanced program is firmonertinib (also known as furmonertinib), a brain-penetrating oral small molecule licensed from Shanghai-based Allist Pharma. This drug is already approved in China. ArriVent has advanced the drug to Phase 3 testing in non-small cell lung cancer driven by EGFR exon 20 insertion mutations.

ArriVent最先进的项目是firmonertinib（也称为furmonertinib），这是一种从上海Allist Pharma授权的穿透大脑的口服小分子药物。这种药物已经在中国获得批准。ArriVent已将该药物推进由EGFR外显子20插入突变驱动的非小细胞肺癌的3期测试。

The ArriVent pipeline also includes two discovery-stage ADCs, one from Aarvik Therapeutics and the other from Jiangsu Alphamab Biopharmaceuticals..

ArriVent管道还包括两个发现阶段的ADC，一个来自Aarvik Therapeutics，另一个来自江苏Alphamab Biopharmaceuticals。。

Exclusive

独家

Improving the Healthcare Financial Experience to Help Care Flow

改善医疗保健财务体验以帮助护理流程

Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.

Zelis首席执行官阿曼达·艾塞尔（AmandaEisel）分享了她对该公司如何解决支离破碎的卫生财务系统问题以造福所有人的观点。

By Stephanie Baum

作者：StephanieBaum

The deal for the Lepu ADC comes nearly a year after

Lepu ADC的交易在将近一年后达成

ArriVent debuted on the Nasdaq with a $175 million IPO

ArriVent以1.75亿美元首次在纳斯达克上市

. ArriVent, which is based in Newtown Square, Pennsylvania, has rights to develop MRG007 for all indications outside of greater China, where Lepu retains rights. Lepu could receive up to $1.16 billion in milestone payments, plus royalties from sales of a commercialized product.

总部位于宾夕法尼亚州纽敦广场的ArriVent有权为大中华区以外的所有适应症开发MRG007，Lepu保留权利。Lepu可以获得高达11.6亿美元的里程碑付款，以及销售商业化产品的版税。

“Expanding our pipeline with MRG007 furthers our mission to develop novel medicines for cancers with high unmet needs worldwide and accelerates our ADC portfolio by adding a program which plans to enter the clinic in the near-term,” Arrivent Chairman and CEO Bing Yao said in a prepared statement. “We look forward to collaborating with Lepu Biopharma in advancing this program globally.”.

Arrivent董事长兼首席执行官姚冰（Bing Yao）在一份准备好的声明中表示：“通过MRG007扩大我们的渠道，进一步推进了我们的使命，即为全球需求未得到满足的癌症开发新药，并通过增加一个计划在近期进入诊所的项目，加速了我们的ADC投资组合。”。“我们期待着与Lepu Biopharma合作，在全球推进这一计划。”。

Image: Getty Images

图片：盖蒂图片

Topics

主题

antibody drug conjugate

抗体-药物偶联物

ArriVent Biopharma

抵达生物制药

biopharma nl

生物制药 nl

cancer

癌症